Jeffrey Moy Sells 4,601 Shares of DexCom, Inc. (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) SVP Jeffrey Moy sold 4,601 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $149.85, for a total value of $689,459.85. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of DXCM stock traded up $1.46 during trading hours on Wednesday, reaching $146.70. 911,812 shares of the company traded hands, compared to its average volume of 1,200,108. DexCom, Inc. has a 12-month low of $105.05 and a 12-month high of $178.45. The company has a debt-to-equity ratio of 1.56, a current ratio of 6.05 and a quick ratio of 5.64. The company has a market cap of $13.26 billion, a P/E ratio of 489.00 and a beta of 0.72. The firm has a 50-day moving average price of $160.01 and a 200 day moving average price of $139.33.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.01 by $0.07. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The company had revenue of $336.40 million during the quarter, compared to analyst estimates of $304.40 million. During the same period in the prior year, the firm posted ($0.10) EPS. The firm’s quarterly revenue was up 38.7% compared to the same quarter last year. Sell-side analysts predict that DexCom, Inc. will post 0.94 EPS for the current year.

Large investors have recently modified their holdings of the business. Gradient Investments LLC bought a new stake in shares of DexCom during the 2nd quarter valued at $25,000. Virtus ETF Advisers LLC purchased a new position in shares of DexCom during the 2nd quarter valued at $29,000. CSat Investment Advisory L.P. purchased a new position in shares of DexCom during the 2nd quarter valued at $31,000. Steward Partners Investment Advisory LLC bought a new position in DexCom in the 2nd quarter worth $31,000. Finally, Wealthcare Advisory Partners LLC bought a new position in DexCom in the 2nd quarter worth $37,000. 96.79% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently commented on the company. Northland Securities reaffirmed a “hold” rating and issued a $125.00 price objective on shares of DexCom in a report on Thursday, June 6th. Piper Jaffray Companies upped their price objective on DexCom from $173.00 to $182.00 and gave the company a “positive” rating in a research report on Wednesday, July 31st. Bank of America increased their target price on DexCom from $162.00 to $185.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Canaccord Genuity raised their target price on DexCom from $160.00 to $185.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Finally, TheStreet upgraded DexCom from a “d+” rating to a “c” rating in a research note on Friday, June 28th. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $168.44.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: Earnings Per Share

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.